Amelioration of Cis-platinum Nephrotoxicity by Orgotein (superoxide Dismutase)

Overview

Journal Physiol Chem Phys

Specialties Biochemistry
Biophysics

Date 1978 Jan 1

PMID 733940

Citations 15

Authors

J E McGinness

P H Proctor

H B Demopoulos

J A Hokanson

D S Kirkpatrick

Affiliations

Soon will be listed here.

Abstract

In rats, daily administration of subcutaneous dose of 2.5 mg/kg of orgotein, the pharmaceutical preparation of Zn-Cu superoxide dismutase, lowers the nephrotoxicity induced by a 5.0 mg/kg dose of the antitumor agent cis-platinum (cis-diaminedichloroplatinum II). The toxicity of cis-platinum was studied by comparative measurements of blood urea nitrogen and changes in body weight, and by comparative renal histology. In addition to their direct clinical applicability, these results support a role for pathologic levels of oxygen radicals in the etiology of the nephrotoxicity of cis-platinum.

Citing Articles

Safety Evaluations of Rapamycin Perfluorocarbon Nanoparticles in Ovarian Tumor-Bearing Mice.

Zhou Q, Harding J, Fan P, Spasojevic I, Kovacs A, Akk A Nanomaterials (Basel). 2024; 14(21.

PMID: 39513832 PMC: 11547995. DOI: 10.3390/nano14211752.

The Investigation of the Antitumor Agent Toxicity and Capsaicin Effect on the Electron Transport Chain Enzymes, Catalase Activities and Lipid Peroxidation Levels in Lung, Heart and Brain Tissues of Rats.

Kursunluoglu G, Taskiran D, Kayali H Molecules. 2018; 23(12).

PMID: 30544766 PMC: 6320812. DOI: 10.3390/molecules23123267.

Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease.

Mapuskar K, Wen H, Holanda D, Rastogi P, Steinbach E, Han R Redox Biol. 2018; 20:98-106.

PMID: 30296702 PMC: 6174865. DOI: 10.1016/j.redox.2018.09.020.

Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.

Schacht J, Talaska A, Rybak L Anat Rec (Hoboken). 2012; 295(11):1837-50.

PMID: 23045231 PMC: 3596108. DOI: 10.1002/ar.22578.

Cisplatin nephrotoxicity: molecular mechanisms.

Hanigan M, Devarajan P Cancer Ther. 2008; 1:47-61.

PMID: 18185852 PMC: 2180401.